The tryptophan–kynurenine pathway in immunomodulation and cancer metastasis

dc.contributor.authorBasson, Charlise
dc.contributor.authorSerem, June Cheptoo
dc.contributor.authorHlophe, Yvette Nkondo
dc.contributor.authorBipath, Priyesh
dc.date.accessioned2023-10-09T11:35:39Z
dc.date.available2023-10-09T11:35:39Z
dc.date.issued2023-09
dc.descriptionDATA AVAILABILITY STATEMENT : Data sharing not applicable to this article as no datasets were generated or analysed during the current study.en_US
dc.description.abstractINTRODUCTION : The activation of the kynurenine pathway in cancer progression and metastasis through immunomodulatory pathways has drawn attention to the potential for kynurenine pathway inhibition. The activation of the kynurenine pathway, which results in the production of kynurenine metabolites through the degradation of tryptophan, promotes the development of intrinsically malignant properties in cancer cells while facilitating tumour immune escape. In addition, kynurenine metabolites act as biologically active substances to promote cancer development and metastasis. METHODS : A literature review was conducted to investigate the role of the tryptophan-kynurenine pathway in immunomodulation and cancer metastasis. RESULTS : Evidence suggests that several enzymes and metabolites implicated in the kynurenine pathway are overexpressed in various cancers. As such, the tryptophan pathway represents a promising target for cancer treatment. However, downstream signalling pathways, including aryl hydrocarbon receptor activation, have previously induced diverse biological effects in various malignancies, which resulted in either the promotion or the inhibition of metastasis. CONCLUSION : As a result, a thorough investigation of the kynurenine pathway and its regulatory mechanisms is necessary in order to properly comprehend the effects of kynurenine pathway activation involved in cancer development and metastasis.en_US
dc.description.departmentAnatomyen_US
dc.description.departmentPhysiologyen_US
dc.description.librarianhj2023en_US
dc.description.sponsorshipThe University of Pretoria, School of Medicine Research Committee (RESCOM) and National Research Foundation (NRF).en_US
dc.description.urihttp://wileyonlinelibrary.com/journal/cam4en_US
dc.identifier.citationBasson, C., Serem, J.C., Hlophe, Y.N. & Bipath, P. The tryptophan–kynurenine pathway in immunomodulation and cancer metastasis. Cancer Medicine 2023; 12: 18691-18701. doi : 10.1002/cam4.6484.en_US
dc.identifier.issn2045-7634 (online)
dc.identifier.other10.1002/cam4.6484
dc.identifier.urihttp://hdl.handle.net/2263/92778
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rights© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.en_US
dc.subjectAryl hydrocarbon receptors (Ahr)en_US
dc.subjectCanceren_US
dc.subjectImmunoregulationen_US
dc.subjectKynurenineen_US
dc.subjectMetastasisen_US
dc.subjectTryptophan pathwayen_US
dc.subject.otherHealth sciences articles SDG-03
dc.subject.otherSDG-03: Good health and well-being
dc.titleThe tryptophan–kynurenine pathway in immunomodulation and cancer metastasisen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Basson_TryptophanKynurenine_2023.pdf
Size:
1.83 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: